Jennifer Lynn Minai-Azary Acquires 40,010 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) Stock

Context Therapeutics Inc. (NASDAQ:CNTX) CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of Context Therapeutics stock in a transaction dated Friday, June 6th. The stock was purchased at an average price of $0.64 per share, with a total value of $25,606.40. Following the completion of the purchase, the chief financial officer now directly owns 80,010 shares of the company’s stock, valued at $51,206.40. The trade was a 100.03% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $0.62 on Thursday. The stock has a market cap of $55.64 million, a P/E ratio of -0.68 and a beta of 1.86. Context Therapeutics Inc. has a one year low of $0.49 and a one year high of $2.75. The company has a fifty day moving average price of $0.75 and a 200 day moving average price of $0.91.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). As a group, equities research analysts anticipate that Context Therapeutics Inc. will post -0.51 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research note on Friday, March 21st. William Blair reiterated an “outperform” rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, May 8th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $6.00.

Institutional Investors Weigh In On Context Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CNTX. MPM Bioimpact LLC bought a new stake in Context Therapeutics in the 4th quarter valued at $15,441,000. Franklin Resources Inc. increased its holdings in Context Therapeutics by 115.9% in the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock valued at $4,204,000 after buying an additional 2,149,392 shares during the period. Allostery Investments LP bought a new stake in Context Therapeutics in the 4th quarter valued at $998,000. Blue Owl Capital Holdings LP increased its holdings in Context Therapeutics by 17.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock valued at $6,676,000 after buying an additional 946,638 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Context Therapeutics by 412.8% in the 4th quarter. Renaissance Technologies LLC now owns 338,435 shares of the company’s stock valued at $355,000 after buying an additional 272,435 shares during the period. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.